The US health regulator has issued a warning letter to drug firm Mylan for violations of good manufacturing norms, including data integrity lapses and failure of quality control at its Nashik facility.
The letter by the United States Food and Drug Administration (USFDA) to the Mylan Pharmaceuticals Inc President Rajiv Malik states that it had inspected the Nashik facility of the company from September 5 to 14, 2016.
